RESUMEN
Background: Myxomas are the most common primary cardiac tumors. Intracardiac myxomas, although benign, could cause serious consequences such as tricuspid or mitral valve obstruction, hemodynamic collapse, and acute heart failure, which pose challenges during anesthetic management. The current study was designed to summarize the anesthetic management of patients undergoing cardiac myxoma resection. Methods: This study was performed retrospectively from the perioperative period of patients who underwent myxoma resection. Patients were divided into two groups according to whether the myxoma prolapsed into the ventricle (group O) or not (group N) to evaluate the impact of tricuspid or mitral valve with obstruction. Results: 110 patients, aged 17-78 years, undergoing cardiac myxoma resection between January 2019 and December 2021 were collected, and their perioperative characteristics were recorded. In the preoperative evaluation, common clinical symptoms included dyspnea and palpitation, whereas embolic events occurred in 8 patients, including 5 (4.5%) cerebral thromboembolic events, 2 (1.8%) femoral artery, and 1 (0.9%) obstructive coronary artery. According to the echocardiography, left atrial myxoma was detected in 104 (94.5%) patients, the average dimension of myxoma was 4.03â cm ± 1.52â cm in the largest diameter, and 48 patients were divided into group O. During intraoperative anesthetic management, hemodynamic instability occurred in 38 (34.5%) patients after anesthesia induction. More patients in group O had hemodynamic instability (47.9% vs. 24.2%, p = 0.009) than in group N. The mean postoperative length of stay in the hospital was 10.64 ± 3.01 days, and most of the patients made an uneventful postoperative recovery. Conclusions: Anesthetic management for myxoma resection can be composed by assessing the myxoma, particularly the echocardiography evaluation and preventing cardiovascular instability. Typically, tricuspid or mitral valve with obstruction is a premier ingredient in anesthetic management.
RESUMEN
OBJECTIVE: To investigate the effects of cattle encephalon glycoside and ignotin injection on serum level of S100B protein and neuron specific enolase (NSE) during cardiac valve replacement with cardiopulmonary bypass (CPB). METHODS: Forty patients undergoing cardiac valve replacement with CPB were randomly divided into two equal groups: cattle encephalon glycoside and ignotin injection group (Group A, injected intravenously with cattle encephalon glycoside and ignotin 20 ml after induction of anesthesia, and control group (Group B, injected intravenously with normal saline instead. Blood samples were taken from the jugular bulb after induction of anesthesia (T1), immediately, and 2 h, 6 h, and 24 h after the discontinuation of CPB (T2, T3, T4, and T5) for determination of serum levels of S100B protein and NSE. RESULTS: The serum levels of S100B protein and NSE of both groups were significantly increased after CPB, and then gradually decreased. At the time point T5, the serum levels of S100B protein of both groups decreased to near the baseline levels (T1 levels), but the serum levels of NSE remained high in both groups. At the time points T2, T3, T4 and T5, the serum levels of S100B protein were significantly higher in Group B than in Group A (all P < 0.05). At the time points T2, T3, and T4, the serum levels of NSE was significantly higher in Group B than in Group A (all P < 0.05). CONCLUSION: Cattle encephalon glycoside and ignotin injection decreases the serum levels of S100B protein and NSE and has cerebral protective effect during cardiac valve replacement with CPB to a certain degree.